--- title: "Institutions are bullish on the recovery cycle of innovative drugs; the Stock Connect Innovative Drug ETF E Fund (159316) attracted over 91 million in net inflows in the past week." type: "Topics" locale: "en" url: "https://longbridge.com/en/topics/43105267.md" description: "As of 9:55, the Hang Seng Stock Connect Innovative Drug Index (HSSCID) rose by 0.8%; among weighted stocks, Innovent Biologics rose 0.45%, BeiGene rose 0.15%, CSPC Pharmaceutical Group rose 0.94%, Akeso rose 2.31%, China National Biotech Group rose 0.59%, Hansoh Pharmaceutical fell 0.43%, Simcere Pharmaceutical fell 1.61%, Kelun-Biotech rose 2.12%, Zai Lab rose 2.54%, and CanSino Biologics-B rose 2.12%. The Hang Seng Stock Connect Innovative Drug ETF E Fund (159316) continues to see capital inflows..." datetime: "2026-07-31T03:34:59.000Z" locales: - [en](https://longbridge.com/en/topics/43105267.md) - [zh-CN](https://longbridge.com/zh-CN/topics/43105267.md) - [zh-HK](https://longbridge.com/zh-HK/topics/43105267.md) author: "[同壁财经](https://longbridge.com/en/profiles/26505347.md)" --- # Institutions are bullish on the recovery cycle of innovative drugs; the Stock Connect Innovative Drug ETF E Fund (159316) attracted over 91 million in net inflows in the past week. As of 9:55, the Hang Seng Stock Connect Innovative Drug Index (HSSCID) rose by 0.8%; among weighted stocks, Innovent Biologics rose 0.45%, BeiGene rose 0.15%, CSPC Pharmaceutical Group rose 0.94%, Akeso rose 2.31%, China National Pharmaceutical Group rose 0.59%, Hansoh Pharmaceutical fell 0.43%, Sansoon Pharmaceutical fell 1.61%, Kelun-Biotech rose 2.12%, Zai Lab rose 2.54%, and Conba-B rose 2.12%. The Stock Connect Innovative Drug ETF E Fund (159316) continues to attract capital inflows. As of the previous trading day, the fund recorded a net inflow of 91.0902 million yuan over the past week, 1.814 billion yuan over the past month, and 6.919 billion yuan over the past year. In terms of news, the "Shanghai Health Development '15th Five-Year Plan'" was recently issued. It mentions increasing support for R&D of innovative drugs and medical devices, strengthening information interoperability and coordination among healthcare, medical insurance, and pharmaceutical sectors, enhancing the application of data in scenarios such as innovative drug R&D, clinical diagnosis and treatment, and commercial health insurance product development, and promoting the construction and application of a medical insurance-empowered innovation development clearing and settlement platform. Guojin Securities stated that the main investment themes for innovative drugs in 2026 will focus on three directions: iteration of frontier technologies, realization of overseas expansion, and inflection points for Biotechs. The pharmaceutical supply chain, benefiting from the resonance of domestic and foreign demand and the volume release of new molecules, is entering a new round of recovery and upward cycle. The management fee rate for the Stock Connect Innovative Drug ETF E Fund (159316) is 0.15%, the custody fee rate is 0.05%, and the comprehensive fee rate is 0.2%. The lower fee rates can effectively reduce cost expenditures for investors. The Stock Connect Innovative Drug ETF E Fund (159316) is currently the only ETF product tracking the Hang Seng Innovative Drug Index in the market, possessing high elasticity and scarcity, helping investors better seize this round of investment opportunities in Hong Kong stock innovative drugs. Related products: Stock Connect Innovative Drug ETF E Fund (159316) E Fund Hang Seng Stock Connect Innovative Drug Feeder Fund Class A (024328) E Fund Hang Seng Stock Connect Innovative Drug Feeder Fund Class C (024329) Innovative Drug ETF E Fund (516080), Off-market feeder (Class A: 019666; Class C: 019667) Stock Connect Healthcare ETF E Fund (513200), Off-market feeder (Class A: 018557; Class C: 018558) Healthcare ETF E Fund (512010), Off-market feeder (Class A: 001344; Class C: 007883) Medical 50ETF E Fund (159847), Off-market feeder (Class A: 017937; Class C: 017938) Bio-tech ETF E Fund (159837), Off-market feeder (Class A: 019324; Class C: 019325) ### Related Stocks - [ONC.US](https://longbridge.com/en/quote/ONC.US.md) - [06990.HK](https://longbridge.com/en/quote/06990.HK.md) - [09926.HK](https://longbridge.com/en/quote/09926.HK.md) - [01093.HK](https://longbridge.com/en/quote/01093.HK.md) - [01177.HK](https://longbridge.com/en/quote/01177.HK.md) - [06160.HK](https://longbridge.com/en/quote/06160.HK.md) - [01530.HK](https://longbridge.com/en/quote/01530.HK.md) - [02162.HK](https://longbridge.com/en/quote/02162.HK.md) - [09688.HK](https://longbridge.com/en/quote/09688.HK.md) - [600109.CN](https://longbridge.com/en/quote/600109.CN.md) - [01801.HK](https://longbridge.com/en/quote/01801.HK.md) - [03692.HK](https://longbridge.com/en/quote/03692.HK.md) - [BGNE.US](https://longbridge.com/en/quote/BGNE.US.md) - [688235.CN](https://longbridge.com/en/quote/688235.CN.md) - [ZLAB.US](https://longbridge.com/en/quote/ZLAB.US.md) - [159316.CN](https://longbridge.com/en/quote/159316.CN.md) - [688336.CN](https://longbridge.com/en/quote/688336.CN.md)